LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "hyperphosphatemia" as a keyword



Signaling pathways involved in vascular smooth muscle cell calcification during hyperphosphatemia

Sign Up to like & get
recommendations! Published in 2019 at "Cellular and Molecular Life Sciences"

DOI: 10.1007/s00018-019-03054-z

Abstract: Medial vascular calcification has emerged as a putative key factor contributing to the excessive cardiovascular mortality of patients with chronic kidney disease (CKD). Hyperphosphatemia is considered a decisive determinant of vascular calcification in CKD. A… read more here.

Keywords: signaling pathways; vascular calcification; vascular smooth; calcification ... See more keywords
Photo from wikipedia

Phosphate Metabolism

Sign Up to like & get
recommendations! Published in 2020 at "Calcified Tissue International"

DOI: 10.1007/s00223-020-00727-x

Abstract: For a long time, phosphate, the anion that incorporates the element phosphorus, has been considered of minor relevance compared to its most studied parent calcium. However, the interest in phosphate metabolism has been remarkably increased… read more here.

Keywords: phosphate metabolism; congenital diseases; hyperphosphatemia; mechanisms underlying ... See more keywords

Hyperphosphatemia is associated with cardiac valve calcification in chronic hypoparathyroidism

Sign Up to like & get
recommendations! Published in 2022 at "Journal of Endocrinological Investigation"

DOI: 10.1007/s40618-022-01770-1

Abstract: To evaluate the association between metabolic abnormalities and cardiovascular risk factors in patients with chronic hypoparathyroidism (HPP). Patients 18 years and older, glomerular filtration > 30 mL/min/1.73 m2 and no documented coronary artery disease were selected. Serum… read more here.

Keywords: risk; hyperphosphatemia; cardiovascular risk; cardiac valve ... See more keywords

Hyperphosphatemia with low FGF7 and normal FGF23 and sFRP4 levels in the circulation characterizes pediatric hypophosphatasia.

Sign Up to like & get
recommendations! Published in 2020 at "Bone"

DOI: 10.1016/j.bone.2020.115300

Abstract: Hypophosphatasia (HPP) is the inborn-error-of-metabolism caused by loss-of-function mutation(s) of the ALPL gene that encodes the tissue-nonspecific isoenzyme of alkaline phosphatase (TNSALP). TNSALP in healthy individuals is on cell surfaces richly in bone, liver, and… read more here.

Keywords: hypophosphatasia; fgf23 sfrp4; hyperphosphatemia low; hyperphosphatemia ... See more keywords

Adsorptivity of cationic cellulose nanocrystals for phosphate and its application in hyperphosphatemia therapy.

Sign Up to like & get
recommendations! Published in 2021 at "Carbohydrate polymers"

DOI: 10.1016/j.carbpol.2020.117335

Abstract: Nanocellulose has gained much attention because of its excellent properties. Cationic cellulose nanocrystals (cCNC) shows good adsorptivity toward negative ions and molecules. Phosphate binders are most used to treat hyperphosphatemia and it is significant to… read more here.

Keywords: cationic cellulose; phosphate; hyperphosphatemia; hyperphosphatemia therapy ... See more keywords

Npt2a as a target for treating hyperphosphatemia

Sign Up to like & get
recommendations! Published in 2022 at "Biochemical Society Transactions"

DOI: 10.1042/bst20211005

Abstract: Hyperphosphatemia results from an imbalance in phosphate (Pi) homeostasis. In patients with and without reduced kidney function, hyperphosphatemia is associated with cardiovascular complications. The current mainstays in the management of hyperphosphatemia are oral Pi binder… read more here.

Keywords: kidney; hyperphosphatemia; npt2a target; target treating ... See more keywords

A safety evaluation of sucroferric oxyhydroxide for the treatment of hyperphosphatemia.

Sign Up to like & get
recommendations! Published in 2021 at "Expert opinion on drug safety"

DOI: 10.1080/14740338.2021.1978973

Abstract: INTRODUCTION Hyperphosphatemia is a common complication as chronic kidney disease (CKD) progresses and most patients undergoing dialysis are prescribed oral phosphate binder therapy to control serum phosphate concentrations. Sucroferric oxyhydroxide is an iron-based phosphate binder… read more here.

Keywords: treatment hyperphosphatemia; hyperphosphatemia; sucroferric oxyhydroxide; safety ... See more keywords

An update on phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a review of safety profiles

Sign Up to like & get
recommendations! Published in 2022 at "Expert Opinion on Drug Safety"

DOI: 10.1080/14740338.2022.2044472

Abstract: ABSTRACT Introduction Hyperphosphatemia is an inevitable complication for patients undergoing dialysis, as is the resulting need for treatment with phosphate binders. Currently, various phosphate binders are clinically available. In addition to their phosphate-lowering activity, individual… read more here.

Keywords: phosphate; hyperphosphatemia; safety profiles; treatment ... See more keywords

#1825 Treating hyperphosphatemia in CKD via targeting Npt2a in the kidney

Sign Up to like & get
recommendations! Published in 2024 at "Nephrology Dialysis Transplantation"

DOI: 10.1093/ndt/gfae069.474

Abstract: Targeting the renal sodium phosphate cotransporter 2a (Npt2a) offers a novel strategy for treating hyperphosphatemia in chronic kidney disease (CKD). In patients with and without reduced kidney function, hyperphosphatemia is associated with cardiovascular complications and… read more here.

Keywords: mice; npt2a inhibition; hyperphosphatemia; kidney ... See more keywords

#1957 Factors associated with hyperkalemia and hyperphosphatemia in non-dialysis dependent CKD: the role of dietary knowledge, attitude, and behaviour

Sign Up to like & get
recommendations! Published in 2025 at "Nephrology Dialysis Transplantation"

DOI: 10.1093/ndt/gfaf116.1438

Abstract: Electrolyte derangements, particularly hyperkalemia and hyperphosphatemia, pose significant challenges in managing non-dialysis dependent chronic kidney disease (CKD) patients. In many middle- to low-income countries, limited data on contributing factors often leaves clinicians with few insights… read more here.

Keywords: knowledge; non dialysis; potassium; hyperkalemia hyperphosphatemia ... See more keywords

Tenapanor: A novel therapeutic agent for dialysis patients with hyperphosphatemia

Sign Up to like & get
recommendations! Published in 2025 at "Therapeutic Apheresis and Dialysis"

DOI: 10.1111/1744-9987.14241

Abstract: Patients on dialysis often develop hyperphosphatemia, contributing to an increased risk of cardiovascular events and mortality. Currently, several types of phosphate binders (PBs) exist for the treatment of hyperphosphatemia, but they are sometimes associated with… read more here.

Keywords: therapeutic agent; tenapanor novel; japan; dialysis ... See more keywords